Trispecific Antibody Development

The ImmuBridge™ platform embodies cutting-edge advancements in oncology and immunotherapy. Leveraging this platform, we can develop trispecific antibodies targeting a variety of immune and tumor cell antigens to activate diverse immune mechanisms, fostering precise and efficient cancer therapeutics.

Overview of Trispecific Antibodies

Trispecific antibodies represent a cutting-edge class of therapeutic molecules, offering a versatile approach to immune-mediated cancer therapy. These antibodies typically incorporate three specific binding domains, enabling them to bridge immune effector cells with tumor cells through distinct antigens. Trispecific antibodies offer a myriad of advantages in the realm of cancer immunotherapy, including:

Fig. 1 Schematic diagram of trispecific antibody-mediated killing of tumor cells by immune cells. (Sun, Yaping, and Jian Xu., 2023)

Advantages of Trispecific Antibodies

Enhanced Targeting

By engaging multiple antigens on tumor cells and immune cells, trispecific antibodies facilitate precise and potent immune responses against cancer, augmenting therapeutic efficacy.

Synergistic Effects

The simultaneous targeting of multiple pathways enhances the anti-tumor immune response, leading to synergistic effects that can overcome tumor heterogeneity and resistance mechanisms.

Reduced Escape Mechanisms

Trispecific antibodies can counteract tumor escape mechanisms by targeting multiple antigens, reducing the likelihood of tumor evasion and disease relapse.

Customizability

The modular nature of trispecific antibody design allows for customization to target specific tumor types, paving the way for personalized cancer therapeutics.

Trispecific Antibody Development

By leveraging the ImmuBridge™ multispecific antibody platform, our team of researchers is empowered to craft tailor-made trispecific antibody constructs renowned for their exceptional targeting precision. Through iterative screening processes and rigorous preclinical validation, these antibodies undergo continuous optimization to enhance both their affinity and specificity.

• TA/CD3/CD137 (4-1BB) Trispecific Antibodies

Our masterpiece is the target antigen (TA)/CD3/CD137 (4-1BB) trispecific antibody. This antibody demonstrates a unique activation pattern dependent on tumor antigen recognition, stimulating both CD3 and CD137 (4-1BB). CD137 is specifically expressed on cytotoxic CD8 T cells activated by tumor antigens, enhancing their tumor-killing function. Engineered to prompt rapid and precise activation of CD8 T cell subsets recognizing tumor antigens, TA/CD3/CD137 (4-1BB) antibody holds promise for accelerating clinical efficacy and enhancing safety profiles.

Fig. 2 Structure of the target antigen (TA)/CD3/CD137 (4-1BB) trispecific antibody.

• Features of TA/CD3/CD137 (4-1BB) Trispecific Antibodies

• TA targeting with high selectivity
• Redirect T cells to cancer cells
• Activate T cells only when TA is engaged
• Cross-linking dependent activity

• IgG like design
• Dual signaling of CD3 and CD137
• Superior preclinical efficacy
• Enhanced drug safety

• Applications of TA/CD3/CD137 (4-1BB) Trispecific Antibodies

The TA/CD3/CD137 (4-1BB) trispecific antibody can be designed to bind with various tumor antigens to meet diverse cancer therapeutic needs.

With the ImmuBridge™ multispecific antibody platform, we can design and develop trispecific antibodies targeting a variety of tumor antigens. These antibodies, compared to bispecific antibodies, can elicit more potent immune responses, reduce tumor evasion, and have a broader range of applications.

We are actively seeking collaborations for licensing our multispecific antibody platform or engaging in co-development of trispecific antibody drug candidates. Feel free to reach out to us to discuss potential partnership opportunities.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.